Sotyktu (deucravacitinib)
- Region
- 🇪🇺 EU
- Active substance
- deucravacitinib
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Authorised
- Therapeutic area
- Psoriasis
- CHMP opinion
- Thu 26 Jan 2023
- EU approval
- Fri 24 Mar 2023
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005755
- ATC
- L04AF07
- Official record
- www.ema.europa.eu
Indication
Plaque psoriasis Sotyktu is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis Sotyktu, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Sotyktu
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.